Meet the Experts


A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Dr. Jonas Anders

Head of Marketing Chromatography, EMD Millipore

Dr. Jonas Anders has more than 15 years of experience in various R&D, marketing and management functions in the area of Life Sciences. He graduated as a chemical engineer at the Technical University in Darmstadt, Germany 1994 and has received his Ph.D. from the University of Mainz in 1998. After that, he worked in various R&D functions at the Karolinska Institute in Stockholm, Sweden and at Merck, KGaA, Darmstadt, Germany, where he joined in 2001. After managing different strategic projects, Jonas took over the business responsibility for Merck´s downstream processing business and is now responsible for Merck Millipore´s global bioprocess purification chromatography business.

Top of page

Michael Bavand

Chief Business Officer and Board Chairman,
ChromaCon, Germany

Michael Bavand, Ph.D., joined ChromaCon in 2009 as an investor and board chairman and has also assumed operational responsibility as a CBO. An entrepreneur helping to found and develop several profitable businesses, Michael has more than 20 years of business, R&D and operational experience gained in the biopharmaceutical industry with assignments at Roche (former Boehringer Mannheim), Serono, Selexis, Siegfried, RCC, and Kuros. A chemist and biologist by training, Michael has also studied International Marketing and has obtained executive education from Stanford Business School (SEP) and Harvard Business School (Operations Strategy). Michael is responsible for Marketing and Sales, BD and Licensing.

Top of page

Nanying Bian Ph.D.

Principal Scientist
EMD Millipore, USA

Nanying Bian is a principal scientist at Process Solutions R&D of EMD Millipore. In the past eight years, she has been focusing on technical innovation in protein purification products, especially new Protein A affinity chromatography resin. As a technical leader, she works closely with a multidisciplinary and multinational team at EMD Millipore, as well as a broad base of biopharmaceutical customers, to successfully launch new chromatography products. Nanying is the inventor and co-inventor of numerous patents on novel technologies for bioprocess purification. Prior to joining Millipore in 2000, Nanying led product development effort at Cabot Corporation’s Inject Colorant Division. Nanying earned her Ph.D. in Chemistry from Princeton University and B. Sc. from Fudan University, Shanghai, China.

Top of page

Gregory S. Blank, Ph.D.

Bioprocess Consultant, USA

Dr. Blank is a recognized global leader in Bioprocess development. He spent over 23 years at Genentech most recently as Director of the Late Stage Purification Department responsible for development of commercial processes, post approval changes, and process validation. Also reporting to Dr. Blank was the virus validation group. He received his Ph.D. in cell biology from the University of Southern California in 1981.

Following post-doctoral fellowships at Case Western University School of Medicine and Becton Dickinson Monoclonal Center he joined the Recovery Sciences Department at Genentech in 1987.He became department director in 2000. TU Darmstadt. He has received several awards, submitted 25 patents and authored more than 50 peer-reviewed papers. While at Genentech he has focused on monoclonal antibody process technology and has led the development and commercial scale-up of recovery processes for both full-length antibodies (including Rituxan, Herceptin, and Raptiva) from mammalian cells and antibody fragments from bacteria. The purification processes Dr. Blank developed for Herceptin and Rituxan have formed the purification platform for all of Genentech’s monoclonal antibodies. He has also helped develop Genentech’s approach to process validation including virus validation, modular validation, and Quality by Design. He has over 40 publications and patents in areas of process development, process validation, manufacturing operations, virus validation, documentation and has lectured extensively in these areas. He currently has an appointment as an Adjunct Professor in the Department of Pharmaceutical Chemistry, University of Kansas and is also on the Scientific Advisory Board of the IBC Life Science Division and the Editorial Board of BioProcessing Journal.

Top of page

Tim Breece

Senior Scientist
Xoma Corporation, USA

Tim Breece is currently a Senior Scientist in Purification Development at Xoma in Berkeley, California, a position he has held since 2009.  Prior to this, he was at Genentech for 24 years with positions in the Technology Assessment, Purification Development and Manufacturing departments. He has submitted four patents, several journal articles and many oral presentations. From 2002-2010, he served as an instructor for the American Society of Mechanical Engineers Bioprocessing Technical Seminars lecturing on chromatography scale-up and monoclonal antibody purification. He received his BS in chemical engineering and applied biology from the University of California at Berkeley.

Top of page

Prof. Dr. Christian Frech

Head of the Institute for Biochemistry
Mannheim University of Applied Sciences, Germany

Prof. Dr. Christian Frech is currently Head of the Institute for Biochemistry at the Mannheim University of Applied Sciences in Germany, a role he has held since 2004. He has also served as the Director of the Steinbeis Transfer Center since 2004.

In 2002, Prof. Dr. Christian Frech was appointed Professor for Bioanalytics at the Mannheim University of Applied Sciences. From 1996-2002, he was the Head of Pilot Plant Protein Purification in the Process Development department at Chiron Behring (now Novartis vaccines) in Marburg, Germany. He completed his postdoctoral work at Boehringer Mannheim (now Roche Diagnostics) in Penzberg, Germany.

Top of page

Trish Greenhalgh Ph.D.

Virology Manager,
Virology and Microbiological Sciences Processing Technologies, EMD Millipore, USA

Trish manages the R&D Virology Group at EMD Millipore. Her group performs virus testing of new products during their development and supports customers in post launch product evaluations. She has 15 years experience in research and development. Prior to joining EMD Millipore, her work involved generation of therapeutic vaccines for a range of clinical indications. She is experienced in all aspects of molecular testing and bioanalytical assay method development and for the past 6 years has been focused on virus clearance evaluations. Trish has a Ph.D. in Biochemistry from University of Leeds, and a Masters in Genetics from Cambridge University, UK.

Top of page

Prof. Dr. Thomas Herget

Head of Processing Technologies
Merck Millipore, Germany

Prof. Dr. Thomas Herget is currently Head of Processing Technologies within the Merck Millipore process solutions division of Merck KGaA, where he develops new methods and materials for bioprocessing. He is also a medical professor at the University of Mainz and a biochemistry professor at the TU Darmstadt. He has received several awards, submitted 25 patents and authored more than 50 peer-reviewed papers.

From 2004-2010, Prof. Dr. Thomas Herget served as the Director, New Technology Evaluation within Merck KGaA’s Chemicals R&D division. In that role, he ran laboratories in Darmstadt (Germany) and oversaw the R&D activities of Novagen (Madison) and Calbiochem (San Diego). In 2000, he joined the Munich-based Axxima Pharmaceuticals AG (now GPC Biotech), a biotech startup founded by Prof. Axel Ullrich, to focus on the development of protein kinase inhibitors in infectious diseases. He became the company’s Director of Therapeutic Indications. In 1998, he was awarded the Boehringer Ingelheim Research Prize and was appointed professor at the University of Mainz in Germany. As a postdoctoral fellow, he had started an independent research group at the university, elucidating signal transduction mechanisms leading to neural differentiation and apoptosis. Also during his postdoctoral work, he studied cell cycle control mechanisms at the Imperial Cancer Research Fund in London, UK. He studied biology and received his PhD working on gene expression profiling during muscle development in Cologne, Germany.

Top of page

Paul Jorjorian

Manager Purification Development, Gallus Biopharmaceutical

Paul Jorjorian joined Gallus Biopharmaceuticals in late 2011 as the lead of the purification development group. His team specializes in the development, tech transfer and scale-up of purification processes for use in cGMP manufacturing. Prior to joining Gallus Paul worked as an Engineer for Bristol Myers Squibb, Syracuse, NY managing multiple development projects for early and late stage products. Paul holds a B.S. in Chemical Engineering with a minor in Management from Purdue University, West Lafayette, IN and a Masters in Chemical Engineering from Cornel University, Ithaca, NY.

Top of page

David W. Kahn, Ph.D.

Senior Director, Purification Sciences

Dr. David Kahn is Senior Director of Purification Sciences at GlaxoSmithKline (GSK) in Rockville, MD, formerly Human Genome Sciences, Inc.

Prior to joining GSK/Human Genome Sciences, Dr. Kahn was a Scientist in the Department of Recovery Sciences at Genentech, Inc., South San Francisco, CA (1992-2002).

Dr. Kahn did post-doctoral training at the University of North Carolina at Chapel Hill (1986-1989) and at Glaxo, Inc., Research Triangle Park, NC (1989-1992). In 1985, he was awarded a Ph.D. in Biochemistry from Virginia Tech (Blacksburg, VA). Dr. Kahn received a B.S. in Biological Sciences from Michigan State University (East Lansing, MI) in 1980.

Phone: 240-314-4411

Top of page

Bettina Katterle, Ph.D

Head of Marketing & Sales, BSL BIOSERVICE Scientific Laboratories GmbH

Dr. Bettina Katterle is currently Head of Sales & Marketing at BSL BIOSERVICE Scientific Laboratories GmbH, Munich. BSL is an internationally active Contract Research Organization (CRO) in the preclinical drug development and part of the Eurofins group. BSL Bioservice / Eurofins Lancaster will offer at the new Biopharmaceutical competence center in Munich services such as viral clearance, biosafety testing and in vitro bioassays. Bettina has been Sales Specialist for Biopharmaceutical Services at Charles River Biopharmaceutical Services from 2009 to 2013. She was responsible for protein characterization including lot release/stability testing as Study Director at NewLab BioQuality AG between 2002 and 2009. She has approximately 15 years experience in protein production, purification, and analytical testing used in protein characterization. Dr. Katterle studied chemistry at the University Bielefeld majoring in chemistry and finished her PhD in the Department of Biophysics. She did research at the Max Planck Institute of Bioinorganic Chemistry in Mülheim/Ruhr using such techniques as CD, EPR, ENDOR and MS.

Top of page

Prof. Dr. Dirk Lütkemeyer

Dirk Lütkemeyer is Professor for Protein Characterisation, Faculty of Engineering and Mathematics, Bielefeld University of Applied Sciences, Germany. He studied biology and received his PhD at the University of Bielefeld 1993. From 1990 to 2005 he worked in the University of Bielefeld as scientist. A one-year postdoctoral work at Pharmacia AB, Sweden was performed during that time.

He co-founder and general director of BIBITEC (founded 2001) a spin-off of the University of Bielefeld, has more than 20 years of experience and expertise in the area of cultivation of mammalian cells and the purification of proteins. He established and headed a production plant for mammalian cells from 2003 to 2007 (Norbitec GmbH). During the same period he was member of the board of Newlab Bioquality AG, a service provider for quality control of biopharmaceuticals. Since 2004 he is “qualified person” in accordance to German medicinal law. His teaching activities as a full Professor (from 2008) are in the area of downstream processing and GMP at the Bielefeld University of Applied Sciences.

Top of page

Prof. Dr. Massimo Morbidelli

Professor for Chemical- and Bioengineering,
ETH Zurich, Switzerland

Massimo Morbidelli, Prof. ETH, PhD, received his PhD in Chemical Engineering at the University of Notre Dame (USA) in 1986. After his first appointments as professor at the University of Cagliari (Italy) and Politecnico di Milano, he is since 1997 Professor at the Institute for Chemical and Bioengineering at ETH Zurich. Massimo Morbidelli is co-author of more than 500 papers, 11 international patents and four books. He serves as a member of the Editorial Board of several international scientific journals, is associate editor of Industrial & Engineering Chemistry Research (ACS) and is a member of the Scientific Advisory Board of the Max-Planck Institute for Dynamics and Complex Technical Systems, Magdeburg, Germany. He is the recipient of the 2005 R.H. Wilhelm Award in Chemical Reaction Engineering of the American Institute of Chemical Engineers.

In the area of preparative chromatography, Massimo Morbidelli did pioneering work for the spreading of SMB-technology as purification process in the pharmaceutical industry. His research group in preparative chromatography belongs to the leading groups in the world.

Since 2007, Massimo Morbidelli is chairman of ChromaCon Ltd., a spin-off company from his research group. ChromaCon Ltd. brings new chromatographic processes (MCSGP-technology) for the purification of proteins and peptides to the market.

Top of page

Venkatesh Natarajan, Ph.D

Applications Engineer,
EMD Millipore

Venkatesh Natarajan is currently a Principal Applications Engineer in the Process Solutions division of EMD Millipore Corporation. His current research focuses on the development of applications and best practices for chromatography and single use manufacturing in a biopharmaceutical setting. His areas of interest include purification, filtration, membrane adsorbers, mixing and computational fluid dynamics. Previously, Mr Natarajan held a position in Systems R&D where he developed processes for handling and packing rigid chromatography resins in process scale columns. Mr Natarajan has been with Millipore for 13 years.

Mr Natarajan holds a Bachelor’s Degree in Chemical Engineering from the Indian Institute of Technology, Mumbai, India. In addition, he holds a Masters and Ph. D. in Chemical Engineering from Rensselaer Polytechnic Institute, Troy, NY. He has presented at several conferences and has published several journal articles in the areas of chromatography and mixing.

Top of page

Franz Nothelfer

Associate Director Protein Science
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

He started his education as biology assistant in 1971 at Dr. Karl Thomae GmbH, a 100% subsidiary of Boehringer Ingelheim Pharma GmbH. In 1979 he joined the newly founded biotechnology group and he started his career in protein chemistry and purification development for recombinant proteins and antibodies. Since 2003 he has served as associate director purification and formulation development at Boehringer Ingelheim Pharma GmbH & Co. KG.

Top of page

Asha Oroskar

President and CEO
Orochem, USA

Dr. Asha Oroskar co-founded Orochem Technologies Inc. in 1996. Prior to starting Orochem, she worked at Nunc, now Thermo-Scientific Nalgene Inc., as part of a team that developed the membrane bottom filter plates and the molecular biology medical devices which evolved into a significant focus for Nalgene Nunc.

At Orochem Technologies, her focus was to develop innovative value-added high throughput devices to serve the biotech and the bioanalytical industry. Her first product at Orochem was a high-throughput synthesis 96-well plate for oligonucleotide synthesis. This plate became an industry-standard format, and led to the implementation of the 384-well format in leading oligo houses.

Asha led the integration of depth prefilters into high-throughput filter plates, a concept first introduced by Orochem into the diagnostic community, and now routinely used for DNA extraction from human tissue samples in the identification of infectious agents. She was the first to develop a protein-precipitation filter-plate concept for carrying out sample clean-up, a procedure routinely applied in bioanalytical samples. Orochem pioneered the bottom-sealed 96-well filter plates to enable the development of affinity, desalting and detergent-removal resin slurry packed plates, furthering high throughput sample prep for the study of Proteomics.

Asha has a Bachelors and Masters from the University of Bombay, and a PhD from the Loyola University of Chicago. Asha’s postdoctoral studies were conducted at the Argonne National Laboratory.

Top of page

Michael Phillips Ph.D

Research Fellow, EMD Millipore, USA

Michael received his Ph.D. in chemical engineering from Rensselaer with a primary focus on preparative-scale chromatographic purification of biomolecules. He has over twenty years experience with EMD Millipore and currently leads a team that is investigating and developing new separation technologies for the downstream purification of biotherapeutics. Michael has authored multiple publications, book chapters, conference presentations, and patents in both bead-based and membrane-based chromatographic separations.

Top of page

Horst Ruppach, Ph.D.

Global Manager of Viral Clearance and
Global Coordinator Virology
Charles River, Biopharmaceutical Services (BPS), Germany

Dr. Horst Ruppach joined Charles River Laboratories with the acquisition of NewLab BioQuality AG in 2008. He studied chemistry at the University of Cologne and the University of Marburg, Germany. He earned his PhD in Human Immunodeficiency Virus (HIV) research in the laboratories of Dr. Rübsamen-Waigmann at the George-Speyer-Haus in Frankfurt. From 1997 to 2005, he and Dr. Andreas Immelmann established Analysis Biomedizinische Test GmbH, an internationally company supplying services in the field of viral safety studies for the pharmaceutical industry. With the fusion of NewLab BioQuality AG and Analysis GmbH in 2005, he developed and managed the virology departments providing virus safety testing for biologicals. Dr. Ruppach has 20 years of experience in the field of virology and is a proven expert for technical and regulatory aspects of virus safety testing and virus/prion clearances studies. He is currently responsible for Charles River’s two virus clearance departments in Cologne, Germany and in King of Prussia, PA.

Top of page

Dr. Michael Schulte

Michael Schulte, Ph.D

Senior Director within the Performance Materials division of Merck KGaA, Darmstadt, Germany

Dr. Michael Schulte is currently a Senior Director within the Performance Materials division of Merck KGaA, a role he has held since January 2011. He has worked in various R&D positions at Merck KGaA since 1995, and has published more than 20 scientific articles and more than 50 conference contributions. He received his PhD working on the synthesis and chromatographic use of chiral polymers at the University of Münster in Germany.

Top of page

Prof. Dr. Hartmut Schlüter

Head of Core Facility Mass Spectrometric Proteomics
Institute of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Germany

Prof. Dr. Hartmut Schlüter is currently Head of Core Facility Mass Spectrometric Proteomics at the Institute of Clinical Chemistry at the University Medical Center Hamburg-Eppendorf (UKE) in Germany. He holds three patents and has published widely on the subject of chromatography, and also serves as the guest editor for Amino Acids and as a reviewer for a variety of scientific journals and funding agencies.

From 2000-2008, Prof. Dr. Schlüter served as the Head of the Bioanalytical Laboratory, Nephrology, at the Charite, University Medicine Berlin. Prior to that role, he was a Group Leader of the Medical Faculty of the Ruhr-University of Bochum in Germany. From 1991-1996, he completed his postdoctoral fellowship in nephrology at the University of Münster. He received his doctorate from the University of Münster’s Institute of Biochemistry in 1991.

Top of page

Tim Schroeder

Tim Schroeder is currently global product manager for MediaScout® products at Atoll GmbH. He has been at the company since 2006 and has been involved in the development of the MediaScout® product lines and commercial launch of RoboColumn®. Tim studied at the University of Applied Sciences, Aachen and completed his diploma thesis on the development of Robocolumn® and system integration at Research Center Jülich, Germany.

Top of page

Romas Skudas, Ph.D

Lab Leader of Process Purification Downstream Technologies, Merck Millipore, Germany

Dr. Romas Skudas is currently a lab leader within Merck Millipore’s Process Purification Downstream Technologies group, a position he has held since 2011. He has worked at Merck Millipore since 2004 on a variety of topics, including the synthesis and characterization of silica particles and the characterization and modeling of optimal silica monolith structures. Dr. Skudas has authored several journal articles and book chapters, and he has presented at a range of industry conferences. He holds a doctorate degree in analytical and inorganic chemistry from Johannes Gutenberg University in Germany.

Top of page

Guido Ströhlein

CEO and Board Member, ChromaCon, Germany

Guido Ströhlein, MBA MTEC ETH, Dr. sc. ETH, Dipl.-Ing., is a co-founder of ChromaCon AG and serves since its incorporation as CEO.

He earned his PhD under the guidance of Prof. Morbidelli in the area of preparative chromatography of proteins and small molecules at the ETH Zürich. In parallel to his PhD, Guido received a MBA in Management, Technology and Economics from the ETH Zürich.

Previously, he obtained his master in chemical engineering from the Technical University Hamburg-Harburg, Germany with stays at the University of Bradford (GB), DOW Chemical, MI, USA in R&D and a diploma thesis in preparative chromatography at Bayer AG, Leverkusen, Germany.

Top of page

Matthew T. Stone, Ph.D.

Research Scientist III
EMD Millipore

Matthew received his Ph.D. in chemistry from the University of Illinois at Urbana-Champaign where his thesis focused on polymeric molecules that mimic the ability of biomolecules to fold into a helical structure in solution. He then continued his research career with postdoctoral positions at the University of Oxford and the Massachusetts Institute of Technology before joining EMD Millipore three years ago. Matthew is a member of the Downstream Technologies team where he has developed new media for flow-through chromatography. During his research career he has authored a variety of different publications and contributed as an inventor to several different patent applications.

Top of page

Prof. Dr. Klaus Unger

Prof. Dr. Klaus Unger

Institute for Inorganic Chemistry and Analytical Chemistry Johannes Gutenberg-University, Mainz, Germany

Prof. Klaus K. Unger studied chemistry at the Technical University of Darmstadt/TUD), Germany, and completed his PhD in 1965 at the Zintl-Institute of Physical Chemistry and Inorganic Chemitry with Prof. H. W. Kohlschuetter. In 1969 he completed his habilitation at the TUD. 1977–2001 he was Professor in Chemistry at the Johannes-Gutenberg University, Mainz, Germany, and since 2001 head of a research group in bioseparations at Merck KGaA, Darmstadt. His research includes the design and synthesis of porous materials as adsorbents and catalysts, surface functionalization and characterization, development of liquid-phase separation methods, and multidimensional LC in proteomics.

Top of page

Pascal Valax, Ph.D.

Director of the Microbial Unit at Merck BioDevelopment
Merck Serono, France

Pascal VALAX is currently the Director of the Microbial Unit at Merck BioDevelopment (Merck Serono, Martillac, France). His main responsibilities include the development and validation of drug substance manufacturing processes for recombinant therapeutic proteins expressed in microbial systems, as well as the production of GMP material for clinical trials.

Until end 2011, he held several positions including Manager of the Downstream Process Development group at Merck-Serono (Vevey, Switzerland), Purification Development Group Leader at Curagen Corporation (New Haven, CT, USA) and Associate Director in the Process Development group at Covance Biotechnology Services (Carry, NC, USA), totaling over 15 years of experience in the development and validation of purification processes for recombinant proteins. He holds a Ph.D. in Chemical Engineering from the University of Texas at Austin.

Top of page

Dr. Chen Wang

Principal Scientist
AbbVie, USA

Chen Wang is a Principal Scientist, Process Sciences at AbbVie Bioresearch Center in Worcester, MA with over 10 years of experiences in purification technology, product and process development. Since joining AbbVie in 2009, she has been leading several early and late phase antibody downstream process development, scale-up, tech transfer, and manufacturing support. In her current role, she is also responsible for evaluating emerging technology, driving innovation and developing next generation platform. Previously, she was a senior scientist in Bioprocess R&D at Millipore and worked on chromatography technology, product and application development. Prior to joining Millipore, Chen received her Ph.D. and M.S. in Chemical Engineering from the Massachusetts Institute of Technology and a B.E. in Chemical Engineering from Tsinghua University, Beijing, China.

Top of page

Gregory Waszak

Principal Scientist
Pfizer Inc.

Greg has worked in Biologics at Pfizer STL for the last 10 years and was in Discovery Research for 16 years prior to that. Greg has purified protein form natural sources as well as from mammalian and bacterial cell lines. Greg has a BS and an MS in biology from the University of Illinois at Chicago.

Top of page